PAVmed director granted 13,930 restricted shares
Baxter Timothy E reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Baxter Timothy E reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Timothy E. Baxter received a grant of 13,930 shares of restricted common stock as equity compensation. These shares vest on May 20, 2029 and may be forfeited if he does not complete the required service period. Following this award, he directly holds 21,097 common shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common stock | 13,930 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
Key Figures
Key Terms
restricted stock financial
Long-Term Incentive Equity Plan financial
vesting financial
forfeiture financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PAVmed (PAVM) director Timothy Baxter report?
What plan governs Timothy Baxter’s PAVmed (PAVM) restricted stock grant?
Was Timothy Baxter’s PAVmed (PAVM) transaction a market purchase or sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.